Applied Filters
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Jazz Pharma’s medical cannabis unit seeks to block generic
UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.
Third Circuit backs pharma firm in antitrust clash
Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.
Voluntary licensing opens up HIV treatment to 100 countries
Medicines Patent Pool deals have given 20 million people access to HIV treatment | Full list of sub-licensees.
Amarin appeals ‘skinny label’ loss
Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Big pharma steps up access, but uneven progress made: report
Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.
SCOTUS rejects BMS vs Gilead patent clash
Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
SCOTUS agrees to hear Amgen revival bid
The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.
Pharma firm voluntarily licences cancer drug in novel deal
Agreement is 'first ever' public health focused voluntary licensing deal on a cancer medicine| Opportunities for generic manufacturers
MSD hit with €39m fine over contraceptive generic delay
The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
